Show simple item record

dc.contributor.authorLorente, D
dc.contributor.authorOmlin, A
dc.contributor.authorZafeiriou, Z
dc.contributor.authorNava-Rodrigues, D
dc.contributor.authorPérez-López, R
dc.contributor.authorPezaro, C
dc.contributor.authorMehra, N
dc.contributor.authorSheridan, E
dc.contributor.authorFigueiredo, I
dc.contributor.authorRiisnaes, R
dc.contributor.authorMiranda, S
dc.contributor.authorCrespo, M
dc.contributor.authorFlohr, P
dc.contributor.authorMateo, J
dc.contributor.authorAltavilla, A
dc.contributor.authorFerraldeschi, R
dc.contributor.authorBianchini, D
dc.contributor.authorAttard, G
dc.contributor.authorTunariu, N
dc.contributor.authorde Bono, J
dc.date.accessioned2016-09-05T12:01:15Z
dc.date.issued2016-12
dc.identifier.citationClinical genitourinary cancer, 2016, 14 (6), pp. 485 - 493
dc.identifier.issn1558-7673
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/96
dc.identifier.eissn1938-0682
dc.identifier.doi10.1016/j.clgc.2016.04.016
dc.description.abstractBackground The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized that the use of clinical and imaging criteria could maximize tissue acquisition from bone marrow biopsies (BMBs). We aimed to develop a score for the selection of patients undergoing BMB.Materials and methods A total of 115 BMBs were performed in 101 patients: 57 were included in a derivation set and 58 were used as the validation set. The clinical and laboratory data and prebiopsy computed tomography parameters (Hounsfield units [HUs]) were determined. A score for the prediction of biopsy positivity was developed from logistic regression analysis of the derivation set and tested in the validation set.Results Of the 115 biopsy specimens, 75 (62.5%) were positive; 35 (61.4%) in the test set and 40 (69%) in the validation set. On univariable analysis, hemoglobin (P = .019), lactate dehydrogenase (P = .003), prostate-specific antigen (P = .005), and mean HUs (P = .004) were selected. A score based on the LDH level (≥ 225 IU/L) and mean HUs (≥ 125) was developed in multivariate analysis and was associated with BMB positivity in the validation set (odds ratio, 5.1; 95% confidence interval, 1.9%-13.4%; P = .001). The area under the curve of the score was 0.79 in the test set and 0.77 in the validation set.Conclusion BMB of the iliac crest is a feasible technique for obtaining tumor tissue for genomic analysis in patients with castration-resistant prostate cancer metastatic to the bone. A signature based on the mean HUs and LDH level can predict a positive yield with acceptable internal validity. Prospective studies of independent cohorts are needed to establish the external validity of the score.
dc.formatPrint-Electronic
dc.format.extent485 - 493
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.subjectBone Marrow
dc.subjectHumans
dc.subjectBone Neoplasms
dc.subjectKallikreins
dc.subjectProstate-Specific Antigen
dc.subjectL-Lactate Dehydrogenase
dc.subjectTomography, X-Ray Computed
dc.subjectBiopsy
dc.subjectBone Marrow Examination
dc.subjectArea Under Curve
dc.subjectProspective Studies
dc.subjectMale
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.subjectBiomarkers, Tumor
dc.titleCastration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.
dc.typeJournal Article
dcterms.dateAccepted2016-04-22
rioxxterms.versionofrecord10.1016/j.clgc.2016.04.016
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.licenseref.startdate2016-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical genitourinary cancer
pubs.issue6
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.publication-statusPublished
pubs.volume14
pubs.embargo.termsNo embargo
icr.researchteamCancer Biomarkersen_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
icr.researchteamTreatment Resistanceen_US
dc.contributor.icrauthorDe Bono, Johannen
dc.contributor.icrauthorAttard, Gerhardten
dc.contributor.icrauthorTunariu, Ninaen
dc.contributor.icrauthorCrespo, Mateusen
dc.contributor.icrauthorNava Rodrigues, Danielen
dc.contributor.icrauthorMateo Valderrama, Joaquinen
dc.contributor.icrauthorMiranda, Susanaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0